Phenotypic subtypes predict outcomes in colorectal cancer

References

• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356.
   PubMed Web of Science ®Google Scholar
• Roepman P, Schlicker A, Tabernero J, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014;134(3):552–562.
   PubMed Web of Science ®Google Scholar
• Budinska E, Popovici V, Tejpar S, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol. 2013;231(1):63–76.
   PubMed Web of Science ®Google Scholar
• Schlicker A, Beran G, Chresta CM, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics. 2012;5(1):15.
   PubMedGoogle Scholar
• Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619–625.
   PubMed Web of Science ®Google Scholar
• De Sousa E Melo F, Wang X, Jansen M, et al. Poor-prognosis Colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614–618.
   PubMed Web of Science ®Google Scholar
• Marisa L, de Reyniès A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLOS Med. 2013;10(5):e1001453.
   PubMed Web of Science ®Google Scholar
• Roseweir AK, Mcmillan DC, Horgan PG, et al. Colorectal cancer subtypes : Translation to routine clinical pathology. Cancer Treat Rev. 2017;57:1–7.
   PubMed Web of Science ®Google Scholar
• Li X, Larsson P, Ljuslinder I, et al. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry. Pathol Res Pract. 2021;220:153379.
   PubMed Web of Science ®Google Scholar
• ten Hoorn S, Trinh A, de Jong J, et al. Classification of colorectal cancer in molecular subtypes by immunohistochemistry. Methods Mol Biol. 2018;1765:179–191.
   PubMedGoogle Scholar
• De La Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28(20):3380–3387.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964.
   PubMed Web of Science ®Google Scholar
• Angell HK, Bruni D, Carl Barrett J, et al. The immunoscore: colon cancer and beyond. Clin Cancer Res. 2020;26(2):332–339.
   PubMed Web of Science ®Google Scholar
• Diao Z, Han Y, Chen Y, et al. The clinical utility of microsatellite instability in colorectal cancer. Crit Rev Oncol Hematol. 2021;157:103171.
   PubMed Web of Science ®Google Scholar
• Katoh M, Katoh M. Molecular genetics and targeted therapy of WNT-related human diseases. Int J Mol Med. 2017;40(3):587–606.
   PubMed Web of Science ®Google Scholar
• Isola JJ, Helin HJ, Helle MJ, et al. Evaluation of cell proliferation in breast carcinoma; comparison of Ki-67 lmmunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990;65(5):1180–1184.
   PubMed Web of Science ®Google Scholar
• van Pelt GW, Sandberg TP, Morreau H, et al. The tumour–stroma ratio in colon cancer: the biologigal role and its prognostic impact. Histopathology. 2018;73(2):197–206.
   PubMed Web of Science ®Google Scholar
• Liu R, Li J, Xie K, et al. FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res. 2013;73(19):5926–5935.
   PubMed Web of Science ®Google Scholar
• Brunelli L, Caiola E, Marabese M, et al. Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget. 2014;5(13):4722–4731.
   PubMedGoogle Scholar
• Kamphorst JJ, Cross JR, Fan J, et al. Hypoxic and ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci USA. 2013;110(22):8882–8887.
   PubMed Web of Science ®Google Scholar
• Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic KRAS maintains pancreatic tumors through regulation of anabolic glucose metabolism Haoqiang. Cell. 2012;149(3):656–670.
   PubMed Web of Science ®Google Scholar
• Hagland HR, Berg M, Jolma IW, et al. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg. 2013;30(1):12–25.
   PubMed Web of Science ®Google Scholar
• Kasurinen J, Hagström J, Kaprio T, et al. Tumor-associated CD3- and CD8-positive immune cells in colorectal cancer: the additional prognostic value of CD8+-to-CD3+ ratio remains debatable. Tumour Biol. 2022;44(1):37–52.
   PubMedGoogle Scholar
• Galon J, Pagès F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1–4.
   PubMed Web of Science ®Google Scholar
• American Joint Committee on Cancer. Colon and rectum. In: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al., editors AJCC cancer staging manual. New York, NY: Springer New York; 2002.
   Google Scholar
• Roseweir AK, Park JH, Hoorn S T, et al. Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. J Pathol Clin Res. 2020;6(4):283–296.
   PubMedGoogle Scholar
• Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16(1):17.
   PubMedGoogle Scholar
• Steele SR, Park GE, Johnson EK, et al. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. Dis Colon Rectum. 2014;57:303–310.
   PubMed Web of Science ®Google Scholar
• Loree JM, Pereira AAL, Lam M, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes Jonathan. Clin Cancer Res. 2018;24(5):1062–1072.
   PubMed Web of Science ®Google Scholar
• Tong G, Zhang G, Liu J, et al. Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC‑8 stratification. Oncol Rep. 2020;43(4):1187–1198.
   PubMed Web of Science ®Google Scholar
• Salminen E, Palmu S, Vahlberg T, et al. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol. 2005;11(21):3245–3249.
   PubMed Web of Science ®Google Scholar
• Luo ZW, Zhu MG, Zhang ZQ, et al. Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis. BMC Cancer. 2019;19(1):13.
   PubMedGoogle Scholar